Evidence map›Paper›PMID 27447549›Full record

ArticleOncotarget2016

Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling.

Yvonne Möller, Markus Morkel, Jens Schmid, Sven Beyes, Janina Hendrick, Michaela Strotbek, Pamela Riemer, Simone Schmid, Lisa C Schmitt, Roland Kontermann and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Accumulation of annexin A2 and S100A10 prevents apoptosis of apically delaminated, transformed epithelial cells.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Review
  4. HER3 in cancer: from the bench to the bedside.Journal of experimental & clinical cancer research : CR · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Yvonne MöllerInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Markus MorkelLaboratory of Molecular Tumor Pathology and Systems Biology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Jens SchmidDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany.
Sven BeyesInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Janina HendrickInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Michaela StrotbekInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Pamela RiemerLaboratory of Molecular Tumor Pathology and Systems Biology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Simone SchmidInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Lisa C SchmittInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Roland KontermannInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Thomas MürdterDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany.
Matthias SchwabDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany.
Christine SersLaboratory of Molecular Tumor Pathology and Systems Biology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Monilola A OlayioyeInstitute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
University of Stuttgart · DECharité - Universitätsmedizin Berlin · DEUniversity of Tübingen · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we study the effects of inducible oncogenic K-Ras (G12V) expression on the polarized morphogenesis of colonic epithelial cells. We provide evidence that the autocrine production of heregulins, ligands for the ErbB3 receptor tyrosine kinase, is responsible for the hyperproliferation and aberrant 3D morphogenesis upon oncogenic K-Ras expression. This is in line with results obtained in primary intestinal organoid cultures, in which exogenous heregulin is shown to interfere with normal tissue architecture. Importantly, ErbB3 inhibition and heregulin gene silencing rescued K-RasG12V-induced features of cell transformation. Together with the increased ErbB3 positivity detected in human high-grade primary colorectal cancers, our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression.

Indexed as

Autocrine CommunicationCell DedifferentiationCell Line, TumorCell PolarityCell ProliferationCell Transformation, NeoplasticColorectal NeoplasmsHumansIntestinal MucosaMorphogenesisras ProteinsReceptor, ErbB-3ERBB3 protein, humanras ProteinsReceptor, ErbB-33D cultureapical-basolateral polarityErbB3/HER3intestinal organoidsoncogenic Ras

Identifiers

PMID27447549
PMCPMC5288203
OpenAlexW2478023009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.